Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIREFLY-1: Tovorafenib in Pediatric RAF-Altered Low-Grade Glioma and Solid Tumors
NCT04775485Phase 2Recruiting
- Sponsor
- Day One Biopharmaceuticals
- Start
- Apr 2021
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of molidustat in glioma, solid tumor, sponsored by Day One Biopharmaceuticals. Started Apr 2021; status: recruiting.
02
Drugs
molidustat
03
Conditions
gliomasolid tumor
Beyond the preview
Go deeper on NCT04775485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775485.